...for breast cancer residual disease LICENSING STATUS: Patent application filed; licensing status unavailable PUBLICATION DETAILS: McDonald...

...the series B funds will enable it to advance ATN-249 through Phase II testing. Andrew McDonald...

...in the U.S. and E.U. as a prophylactic. According to Attune's co-founder and CEO Andrew McDonald...
...volunteers. The company plans to start and complete a Phase II trial in 2019, said McDonald...

...the series B funds will enable it to advance ATN-249 through Phase II testing. Andrew McDonald...

...amines. The non-profit is not a member of the in silico toxicology protocols consortium. Scott McDonald...

...Mass.) hired Shane Kovacs as chief business and chief financial officer. Kovacs succeeds CFO Brian McDonald...

...2017, academic investigators could apply for manufacturing slots that were reserved for intramural research. Cheryl McDonald...

...that lets researchers access all of the DRIVE study data. Novartis senior oncology researcher Robert McDonald...
...in common between these 15 cell lines that’s different than the other 385 lines?'' said McDonald...
...CCLE cell lines, and made the data accessible so researchers could explore the interactions independently. McDonald...

...payers do reimburse for non-hospital lodging during treatment. Additionally, she said resources like the Ronald McDonald...
...NICE), London, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Ronald McDonald...

...were the JDRF T1D Fund, Black Beret Life Sciences and an investor group led by McDonald...